After sharing plans to shutter last summer, Asarina Pharma has managed to sell off its Tourette syndrome candidate to Relmada Therapeutics, another struggling biotech. Relmada, which has turned to ...

Relmada Therapeutics has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid developed for treating Tourette syndrome (TS) and related compulsive disorders, from Asarina Pharma ...

Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed for the potential treatment of Tourette syndrome and ...

RELMADA ACQUIRES NEUROSTEROID FROM ASARINA: Relmada Therapeutics (RLMD) announced Thursday the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma, being developed for ...

(RTTNews) - Relmada Therapeutics, Inc. (RLMD), a clinical-stage biotechnology company, on Thursday announced the acquisition of Sepranolone, a Phase 2b-ready neurosteroid, from Asarina Pharma AB.